Published in J Clin Oncol on August 01, 2003
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol (2011) 3.22
More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg (2006) 2.78
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst (2008) 2.46
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer (2013) 1.77
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conference. Int J Colorectal Dis (2014) 1.69
Does a laparoscopic approach affect the number of lymph nodes harvested during curative surgery for colorectal cancer? Surg Endosc (2009) 1.67
Short term results of complete (D3) vs. standard (D2) mesenteric excision in colon cancer shows improved outcome of complete mesenteric excision in patients with TNM stages I-II. Tech Coloproctol (2013) 1.66
Is there a disadvantage to radical lymph node dissection in colon cancer? Int J Colorectal Dis (2012) 1.61
Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg (2012) 1.55
Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut (2007) 1.47
Laparoscopic colectomy for cancer and adequate lymphadenectomy: association between survival and number of lymph nodes. Surg Endosc (2006) 1.40
Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer (2010) 1.34
Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol (2011) 1.32
Positive lymph node retrieval ratio optimises patient staging in colorectal cancer. Br J Cancer (2009) 1.32
Laparoscopic complete mesocolic excision for right colon cancer. Surg Endosc (2012) 1.29
Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol (2009) 1.26
Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital? J Gastrointest Surg (2010) 1.20
Lymph node metastasis of carcinomas of transverse colon including flexures. Consideration of the extramesocolic lymph node stations. Int J Colorectal Dis (2014) 1.14
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Lymph node harvest in colon and rectal cancer: Current considerations. World J Gastrointest Surg (2012) 1.11
Challenges in the management of stage II colon cancer. Semin Oncol (2011) 1.09
Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg (2004) 1.09
Comparison of conventional laparoscopic and hand-assisted oncologic segmental colonic resection. Surg Endosc (2007) 1.09
Prognostic and survival analysis of 837 Chinese colorectal cancer patients. World J Gastroenterol (2013) 1.09
Prognostic value of the lymph node ratio in node positive colon cancer. Gut (2006) 1.07
Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients. World J Surg (2012) 1.07
The impact of surgical technique on neck dissection nodal yield: making a difference. Eur Arch Otorhinolaryngol (2015) 1.05
Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. PLoS One (2014) 1.05
The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer (2007) 1.05
Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis (2013) 1.05
Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Ann Surg (2010) 1.03
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer (2011) 1.02
High lymph node yield is related to microsatellite instability in colon cancer. Ann Surg Oncol (2011) 1.00
Impact of socioeconomic status on extent of lymph node dissection for colon cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer. World J Surg (2012) 0.99
Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg (2010) 0.98
Impact of metastatic lymph node ratio in node-positive colorectal cancer. World J Gastrointest Surg (2010) 0.98
Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIB and IIIC rectal cancer treated with preoperative radiotherapy. Oncotarget (2014) 0.98
The sentinel node procedure in colon carcinoma: a multi-centre study in The Netherlands. Int J Colorectal Dis (2007) 0.98
The impact of age on quality measure adherence in colon cancer. J Am Coll Surg (2011) 0.96
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer (2007) 0.96
Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol (2009) 0.96
Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res (2007) 0.95
Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age. Int J Colorectal Dis (2011) 0.95
Complete mesocolic excision with D3 lymph node dissection in laparoscopic colectomy for stages II and III colon cancer: long-term oncologic outcomes in 168 patients. Tech Coloproctol (2014) 0.95
Laparoscopic surgery for colon cancer: a review of the fascial composition of the abdominal cavity. Surg Today (2014) 0.93
Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer (2014) 0.92
Debating deposits: an interobserver variability study of lymph nodes and pericolonic tumor deposits in colonic adenocarcinoma. Arch Pathol Lab Med (2013) 0.92
D3 lymphadenectomy using a medial to lateral approach for curable right-sided colon cancer. Int J Colorectal Dis (2008) 0.92
Factors affecting lymph node yield from patients undergoing colectomy for cancer. Int J Colorectal Dis (2011) 0.92
Close collaboration between surgeon and pathologist is essential for accurate staging of early colon cancer. Ann Surg (2007) 0.92
Lymph node counts and survival rates after resection for colon and rectal cancer. Gastrointest Cancer Res (2009) 0.91
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res (2009) 0.91
The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. World J Surg (2009) 0.91
Molecular staging individualizing cancer management. J Surg Oncol (2012) 0.90
The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients. World J Surg (2013) 0.90
Colorectal cancer and lymph nodes: the obsession with the number 12. World J Gastroenterol (2014) 0.90
Integrated ratio of metastatic to examined lymph nodes and number of metastatic lymph nodes into the AJCC staging system for colon cancer. PLoS One (2012) 0.90
Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis (2014) 0.90
Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol (2004) 0.90
Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer. J Hematol Oncol (2011) 0.89
The complexity of the count: considerations regarding lymph node evaluation in colorectal carcinoma. J Gastrointest Oncol (2012) 0.89
Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute. Int J Colorectal Dis (2009) 0.89
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
The impact of audit and feedback on nodal harvest in colorectal cancer. BMC Cancer (2011) 0.87
Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg (2009) 0.87
Extended lymph node dissection in colorectal cancer surgery. Reliability and reproducibility in assessments of operative reports. Int J Colorectal Dis (2009) 0.87
Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution. Int J Colorectal Dis (2010) 0.87
Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med (2010) 0.86
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative. Clin Colorectal Cancer (2011) 0.86
Laparoscopic complete mesocolic excision: West meets East. World J Gastroenterol (2014) 0.86
Laparoscopic rectal cancer surgery: where do we stand? World J Gastroenterol (2012) 0.86
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer (2016) 0.86
Lymph-node ratio is an independent prognostic factor in patients with stage III colorectal cancer: a retrospective study from the Middle East. World J Surg Oncol (2012) 0.85
Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. J Am Coll Surg (2015) 0.85
Extent of surgery in cancer of the colon: is more better? World J Gastroenterol (2015) 0.85
A nodal positivity constant: new perspectives in lymph node evaluation and colorectal cancer. World J Surg (2013) 0.84
Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer (2016) 0.84
Metastatic lymph node ratio as an independent prognostic variable in colorectal cancer: study of 113 patients. Tech Coloproctol (2009) 0.84
Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy. Sci Rep (2015) 0.84
Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer. Oncol Lett (2013) 0.84
Laparoscopic lymphatic mapping and sentinel lymph node detection in colon cancer: technical aspects and preliminary results. Surg Endosc (2007) 0.83
Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J Surg Oncol (2012) 0.83
[Acetone treatment of lymph node preparations in staging colorectal specimens]. Pathologe (2007) 0.83
Adequate lymph node examination is essential to ensure the prognostic value of the lymph node ratio in patients with stage III colorectal cancer. Surg Today (2011) 0.82
Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. Ther Adv Med Oncol (2010) 0.82
Detection of lymph node metastases in human colorectal cancer by using 5-aminolevulinic acid-induced protoporphyrin IX fluorescence with spectral unmixing. Int J Mol Sci (2013) 0.82
Impact of lymph node ratio as a valuable prognostic factor in gallbladder carcinoma, focusing on stage IIIB gallbladder carcinoma. J Korean Surg Soc (2013) 0.82
Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg (2016) 0.82
Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. Ann Gastroenterol (2016) 0.82
Lymph node ratio as a predictor of outcome in patients with oropharyngeal cancer. Eur Arch Otorhinolaryngol (2013) 0.81
Prognostic factors in node-negative colorectal cancer: a retrospective study from a prospective database. Int J Colorectal Dis (2010) 0.81
Management of nodal disease from colon cancer in the laparoscopic era. Int J Colorectal Dis (2014) 0.81
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Carcinoid tumors. N Engl J Med (1999) 6.44
Gastric carcinoma. N Engl J Med (1995) 5.77
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Does the placement of surgical clips within the excision cavity influence local control for patients treated with breast-conserving surgery and irradiation. Int J Radiat Oncol Biol Phys (1996) 2.76
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol (1991) 2.46
Primary central nervous system lymphoma. Ann Intern Med (1993) 2.36
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35
Survival after postoperative combination treatment of rectal cancer. N Engl J Med (1986) 2.24
Carcinoma of the anal canal. N Engl J Med (2000) 2.22
Temperature and Excitability. J Physiol (1896) 2.21
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol (1992) 1.98
Chemoprevention of colorectal cancer. N Engl J Med (2000) 1.98
Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol (1999) 1.95
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med (2000) 1.90
Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys (1999) 1.89
Gaseous pollutants in particulate matter epidemiology: confounders or surrogates? Environ Health Perspect (2001) 1.88
Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol (2001) 1.87
Goodness-of-fit for GEE: an example with mental health service utilization. Stat Med (1999) 1.81
An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun (1970) 1.79
Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med (2000) 1.79
Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys (2000) 1.71
Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol (1999) 1.70
Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.65
Hearing preservation in vestibular schwannoma surgery: what factors influence outcome? J Neurosurg (1995) 1.64
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology. Biometrics (1999) 1.62
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol (2002) 1.62
Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol (1996) 1.59
Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry (1989) 1.57
A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin. Neurosci Lett (1988) 1.55
Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. Int J Radiat Oncol Biol Phys (1996) 1.55
Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. Int J Radiat Oncol Biol Phys (1995) 1.55
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
Management of the vertebral artery in excision of extradural tumors of the cervical spine. Neurosurgery (1995) 1.54
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 1.52
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol (1993) 1.52
Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol (1990) 1.51
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50
Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol (2001) 1.48
Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. Int J Radiat Oncol Biol Phys (1990) 1.48
Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am (1999) 1.47
Using time- and size-resolved particulate data to quantify indoor penetration and deposition behavior. Environ Sci Technol (2001) 1.44
Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys (1996) 1.43
Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol (2000) 1.42
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med (1988) 1.41
A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer (1998) 1.41
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Diffuse Lewy body disease. Lancet (1989) 1.40
The abnormal isoform of the prion protein accumulates in late-endosome-like organelles in scrapie-infected mouse brain. J Pathol (1995) 1.40
Evidence for cure of 'young' men with prostate cancer. Oncology (Williston Park) (2001) 1.40
Lymphography in carcinoma of the uterus. Clin Radiol (1972) 1.38
Local surgical treatment of rectal cancer. Cancer Invest (1995) 1.38
Regulation of enzyme turnover during tissue differention. Studies on the effects of hormones on the turnover of fatty acid synthetase in rabbit mammary gland in organ culture. Biochem J (1975) 1.38
alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol (1992) 1.38
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol (1997) 1.36
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol (1999) 1.36
Role of lymphography in carcinoma of the prostate. Br Med J (1975) 1.34
Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys (1998) 1.34
Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air pollutants in the St Louis, Missouri metropolitan area. Occup Environ Med (2006) 1.33
Observations on the growth of tumours in lymph nodes changing from normal to abnormal while remaining opacified after lymphography. Clin Radiol (1968) 1.31